Subscribe

  • How Can We Help You?

    Global Problem Solving from Covington: Deal with Complex Problems Anywhere in the World

    • Apr 08, 2021

Anna Zhao

Special Legal Consultant

Washington +1 202 662 5449

English
  • About
  • Representative Matters
  • Credentials
  • About

    Anna Zhao advises clients on a broad range of regulatory, compliance, transactional, and legislative matters in the life sciences industry.

    Anna focuses on counseling pharmaceutical and biotechnology companies and industry associations on:

    • clinical trials,
    • informed consents,
    • regulatory applications and approvals,
    • FDA expedited programs,
    • orphan drugs,
    • promotion and scientific exchange,
    • quality and manufacturing, and
    • priority review vouchers.

    Drawing on her regulatory knowledge and expertise, Anna regularly assists clients with mergers and acquisitions, capital market transactions, and life sciences collaboration and licensing matters and various agreements and filings that are often associated with these transactions. As part of her transactional practice, Anna advises clients on assessing regulatory risks and mitigating them to achieve commercial objectives.

    In addition, Anna represents clients in complex government enforcement actions and internal investigations on a variety of issues, including clinical trial, manufacturing, and marketing and sales compliance issues.

    Anna is qualified to practice Chinese law, admitted to practice in the State of New York, and licensed in the District of Columbia as a Special Legal Consultant.

    Areas of Expertise

  • Practices and Industries
  • Representative Matters
    • Counseled pharmaceutical and biotechnology clients on clinical trials and drug approvals, informed consents, and orphan-drug designation and exclusivity issues.
    • Advised pharmaceutical clients on cGMP compliance and quality issues.
    • Drafted policies and procedures on promotion and scientific communications for medical products.
    • Advised pharmaceutical clients on NDA and BLA filing issues.
    • Advised pharmaceutical clients on interactions with healthcare professionals.
    • Conducted FDA regulatory review for UCB in its $2.1 billion acquisition of Ra Pharmaceuticals.

    • Conducted FDA regulatory review for Merck in its $2.7 billion acquisition of ArQule; $1.05 billion acquisition of Peloton Therapeutics; and $425 million acquisition of OncoImmune.
    • Advised Bayer in its sale of Coppertone business Beiersdorf AG and Dr. Scholl’s business to Yellow Wood Partners.
    • Counseled business on managing the life cycle of pharmaceutical products.
    • Represented a major pharmaceutical company in numerous internal investigations concerning sales and marketing practices.
    • Represented a major financial institution in government investigations of foreign bribery relating to hiring practices.
    • Represented an employee at a major bank on issues arising under the False Claim Act.
    • Advised companies and business associations regarding commitments of foreign governments under World Trade Organization (WTO) rules and free trade agreements.
    • Advised a leading payment card association on the WTO dispute settlement proceedings and electronic payment services regulations in China.
    • Assisted various clients in analyzing Chinese government’s approval process and restraints on foreign investment.

    Areas of Expertise

  • Credentials
    Education
    • The University of Chicago Law School, LL.M., 2015
    • China University of Political Science & Law, LL.M., 2011
        • With honors
    • China University of Political Science & Law, B.A., 2009
    Bar Admissions
    • District of Columbia: Special Legal Consultant
    • New York
    • PRC Bar Qualification
    Languages
    • English
    • Mandarin
    Memberships and Affiliations
    • American Bar Association
    • New York State Bar Association
    • Sino-American Pharmaceutical Professionals Association

    Areas of Expertise

News and Insights